Additional PET/CT Tracer to Detect Prostate Cancer
Researchers identify 18F-PMSA-1007 as an equally effective radiopharmaceutical for detecting prostate cancer.
Researchers have identified a second radiopharmaceutical that nuclear medicine departments can keep in mind when staging prostate cancer.
According to a study published in the April issue of the Journal of Nuclear Medicine, investigators in Israel determined 18fluorine prostate-specific membrane antigen-1007 (18F-PMSA-1007) can accurately pinpoint malignant prostate cancer lesions.
The team, led by Einat Evan-Sapir, M.D., Ph.D., from Tel Aviv Sourasky Medical Center, said this additional radiopharmaceutical likely has a longer half-life and better spatial resolution than 68gallium-PSMA-11 (68Ga-PMSA-11). According to the study details, 18F-PMSA-1007’s half-life is 110 minutes, and 68Ga-PMSA-11’s is 68 minutes. 68Ga-PSMA-11 also emits a higher-energy positron.
To determine efficacy, the team compared how well 18F- PMSA-1007 diagnosed prostate cancer to how well 68Ga-PSMA-11 performed with PET/CT scans. They evaluated 16 patients who were awaiting radical prostatectomy for newly-diagnosed intermediate- or high-risk prostate cancer. They, then, compared the outcomes with both radiopharmaceuticals with the gold standard of histopathologic findings.
Both 18F-PMSA-1007 and 68Ga-PMSA-11 identified the same location of radiolabeled PSMA-avid lesions in the prostate. However, 18F-PMSA-1007 pinpointed additional findings in four patients – three were confirmed as prostate cancer, and one was determined to be chronic prostatitis.
The results indicate an interchangeability between the radiopharmaceuticals, the team said.
“In view of the near-equal performance of the two traces, this preliminary study suggest the routine use of 18F-PMSA-1007 in lieu of 68Ga-PMSA-11 for staging prostate cancer patients, and clinicians can use either radiotracer based on availability,” the team wrote.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
